News
Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback